Shanghai Henlius Biotech Inc. (HKG: 2696) has published its 2024 financial results, recording revenues of RMB 5.72 billion (USD 788 million), representing a 6.1% year-on-year (YOY) increase. Net profits reached RMB 820.5 million (USD 114 million), up 50.3% YOY, reflecting strong performance across its product portfolio.
Core Product Performance
Henlius Biotech continued to focus on high-incidence oncology areas such as breast cancer, lung cancer, and gastrointestinal cancer. Six core products collectively generated RMB 4.9 billion (USD 680 million) in sales, an 8.3% YOY increase. Notable contributors included Hanquyou (trastuzumab biosimilar) with RMB 2.8 billion (USD 387 million), PD-1 inhibitor HanSiZhuang (serplulimab) with RMB 1.3 billion (USD 181 million), and Hanbeitai (bevacizumab biosimilar) with RMB 197.1 million (USD 27 million). Neratinib, licensed from Convalife Pharmaceuticals, contributed RMB 45.3 million (USD 6.2 million), while Hanlikang (rituximab biosimilar) generated RMB 550 million (USD 76 million) in sales and licensing income, and HanDaYuan (adalimumab biosimilar) achieved RMB 40.1 million (USD 5.5 million) in sales.
Research and Development
The company’s R&D investment reached RMB 1.84 billion (USD 2.5 billion), a 28.4% YOY increase, underscoring its commitment to innovation and product development.
Manufacturing and Quality Management
Henlius Biotech is enhancing its manufacturing operations and quality management system. The company has established a commercial production capacity of 48,000 liters to ensure stable supplies across key markets, including China, Southeast Asia, North America, Europe, the Middle East, and Latin America.-Fineline Info & Tech
Leave a Reply